This week in drug discovery (23-27 September)
News round-up for 23-27 September by DDW Senior Digital Content Editor Diana Spencer.
The publication of DDW’s latest eBook on immunotherapy has coincided with some interesting developments in this therapy area, particularly monoclonal antibodies, including two new regulatory approvals.
The top stories:
Innovent updates ESMO 2024 on mAbs in solid tumours
Innovent Biologics revealed clinical data on two of its mAb (monoclonal antibody) programmes at the 2024 ESMO Congress.
Triple combination treatment shrinks lung cancer tumours in mice
Researchers at the Francis Crick Institute, in collaboration with Revolution Medicines, have shown that a combination of treatments in mice with lung cancer allow immunotherapies to target non-responsive tumours.
Where are the opportunities and advances in immunotherapy?
A new eBook, sponsored by Sino Biological, examines the latest innovations that are driving the market and overcoming the challenges associated with these treatments.
EU CHMP recommends new indication for AZ’s benralizumab
AstraZeneca’s Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
FDA approves Sarclisa combination for multiple myeloma
The US Food and Drug Administration (FDA) has approved Sanofi’s anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa) for newly diagnosed multiple myeloma.